

2018 Global Pharma & Biotech Symposium

Access to China: Market, Regulation, Science, Investment and Solutions



GPBS

Global
Pharma & Biotech
Symposium

September 14/15
Basel, Switzerland



Please scan the Quick Response Code above by Facebook, Twitter or Wechat to join

You are cordially invited to join 2018 Global Pharma & Biotech Symposium hosted by Global Innovative Drug China Investment Fund and organized by SDIC fund Management and Asymchem on 14th and 15th September in Basel. Before the Symposium, we will be part of the 2nd Swiss-Chinese Life Sciences Forum, which is jointly organized by Basel Area Swiss, Swiss-Chinese Chamber of Commerce and FHNW at Novartis Campus, Basel on 13th September. Companies interested in promoting their drugs in the world's second largest pharmaceutical market and/or raising capital from this active investment market should not miss this opportunity and one-on-one meetings, which will show you the roadmap to the China market through the capital market and the CDA issue. Come and connect with Asymchem/ SDIC fund Management.

The Chinese pharmaceutical market is undergoing unprecedented change. Not only is it the second largest pharmaceutical market in the world, but it also continues to grow at a rapid pace. Facing the challenges of new technology and regulation optimization, Chinese scientists and investors are enhancing their technique realization. Furthermore, foreign companies will have more opportunities to gain broad access to the Chinese market.

SDIC Fund Management is an independent private equity fund management, established in 2009 with sophisticated investment experience. Asymchem is a global CDMO with more than 20 years of experience in IND and NDA in China. We boast a strong partnership line-up. Dr. He Ruyi is an experienced expert from China's National Academy of Sciences and the Center of Drug Evaluation at the China National Drug Administration (CNDA). SDIC Fund Management will be represented by Dr. Jack Yin who is the Managing Director. Covance, the world's most comprehensive drug development company, will be represented by Dr. Levvy Lv, who is the Senior Director of Scientific Engagement and Clinical Development of the company. Dr. James Gage, Chief Scientific Officer of Asymchem, will also be here.

We are looking forward to seeing you in Switzerland.

Global Innovative Drug China Investment Fund

Access to China: Market, Regulation, Science, Investment and Solutions

13th - 15th, September, Launchlabs, Basel

Time/ Date	Event & Location	Items
1:30-6:30PM 13th, Sep.	Swiss-Chinese Life Sciences Forum 2018, Novartis Campus, Basel	Regulation reform in China Dr. Ruyi He, Chief Scientist of CNDA drug review center
8:30-12:00AM 14th, Sep.	Symposium Launchlabs, Basel	1) Regulation reform in China – How to Rapidly Bring Innovative Drugs to Market Dr. Ruyi He, Chief Scientist of CNDA drug review center 2) Opportunity and Challenge: Biomedical Investment in China Market Dr. Jack Yin, Managing Director of SDIC Fund Management 3) China as Part of Global Ecosystem for Pharmaceutical R&D Person TBD from a leading EU pharma, regional head of its China branch 4) Strategies for Multi-Region Clinical Trials in China-How to Maintain Efficient Use of Resources and Ensure Compliance with Local and National Regulations Dr. Levvy Lv, Senior Director, Scientific Engagement and Clinical Development of Covance 5) Asymchem Service Report Dr. James Gage, Chief Scientific Officer of Asymchem.
12:00-2:00PM 14th, Sep.		Flying lunch & networking
1:30-5:00PM 14th, Sep.	Launchlabs, Basel	One on one meeting
8:30-12:00AM 15th, Sep.		One on one meeting
12:00-2:00PM 15th, Sep.	Launchlabs, Basel	Flying lunch & networking
1:30-5:00PM 15th, Sep.	Launchlabs, Basel	One on one meeting

Host

Global Innovative Drug
China Investment Fund

Organizer



Co-organizer



Speaker Introduction



Dr. Ruyi He

Dr. Ruyi He is the Chief Scientist at China National Drug Administration (CNDA) used to be recognized as cFDA. Dr. He joined the CNDA in July 2016 after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He has received many awards, including the FDA excellence in Review Science Award, CDER Leadership Excellence Award, CDER Excellence in Mentoring Award, FDA Award of Merit, and the Department of Health and Human Service Secretary's Award for Distinguished Service.



Dr. Jack Yin

Dr. Jack Yin is Managing Director of SDIC fund Management Company and he is dedicated to investment in biomedical and pharmaceutical industry. Dr. Yin had in-depth biomedical industry experience. He ever worked with biotech startup as well as top pharmaceutical company, responsible for drug discovery and development as well as project management. When he moved back to China, Dr. Yin worked with top research organization responsible for education, research and management related to biomedical science. Besides, Dr. Yin worked as Associate Director, cooperate finance consulting of PwC. Dr. Yin has B.Sc. and M.Sc. of Nankai University and Ph.D. of National University of Singapore.



Dr. Levvy Lv

Dr. Levvy Lv is Senior Director, Scientific Engagement and Clinical Development for Covance. Prior to joining Covance in 2017, he worked in early and late clinical development in pharmaceutical industry. He has rich experience of leading both early and late clinical programs in China and the whole Asia Pacific region. Dr. Lv is also the dual-filing task force leader to help clients file CTA in China and in other countries like US, Australia, New Zealand, Netherlands in parallel. Dr. Lv is a Clinical Pharmacologist by training, is frequent speaker of top congresses such as American Society of Microbe 2016, Asian Pharmacometrics Congress 2017, New Drug Advancement Association Annual Meeting 2017, China Anti Cancer Association annual meeting 2017 et al.



Dr. James Gage

Dr. Gage is Chief Scientific Officer of Asymchem. He earned his Ph.D. in Chemistry with Professor David Evans at Harvard University. Dr. Gage has 26 years of experience in process chemistry and other aspects of pharmaceutical CMC. Prior to joining Asymchem in early 2006, Dr. Gage worked in process chemistry and pharmaceutical development in the US pharma industry for 14 years. He manages implementation of commercial processes at Asymchem and seeks ways to expand the company's capabilities through development and application of new technology.



For more info within China, please contact
Nan Xia at tel: +86 (138) 1801-5889
Email: xianan@asymchem.com.cn

For questions or inquiries within the Europe, please contact
Jordi Robinson at +44(0)7979 036 012
Email jordi@asymchem.com